查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586047

癌症生物疗法市场：副产品、给药途径和最终用户 - 全球预测 2025-2030

Cancer Biological Therapy Market by Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines), Route of Administration (Intramuscular, Intravenous, Subcutaneous), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症生物治疗市场价值为649.5亿美元，预计到2024年将达到724.2亿美元，复合年增长率为11.60%，到2030年将达到1400.4亿美元，预计将达到1000万美元。

癌症生物疗法，也称为免疫疗法，包括单株抗体、疫苗和细胞激素疗法等多种方法，利用人体的免疫系统来锁定和对抗癌细胞。随着癌症发生率持续上升，人们越来越需要比化疗和放射线治疗等传统方法副作用更少的创新治疗方法。这种生物学上多样化的治疗方法在多种癌症类型中具有重要的应用，包括黑色素瘤、乳癌和白血病。最终用途范围主要包括医院、专门的癌症治疗中心和研究机构，可根据患者独特的癌症特征开发客製化的生物疗法。

主要市场统计
基准年[2023] 649.5亿美元
预测年份 [2024] 724.2亿美元
预测年份 [2030] 1400.4亿美元
复合年增长率（%） 11.60%

市场成长主要是由生技药品管道的扩大和监管核准的增加以及生物技术的技术进步和对癌症基因组学的更深入了解所推动的。潜在的机会在于对个人化医疗的需求不断增长，以及针对以前难以治疗的癌症的新治疗方法的快速开发。为了利用这一点，公司需要投资新一代抗体偶联物和基于细胞的免疫疗法的研究和开发。然而，该市场面临高处理成本、复杂的製造流程和严格的监管要求等挑战，这些都减缓了商业化进程。

可以透过增强药物输送系统来提高疗效和患者便利性，并探索使用人工智慧进行个人化治疗方法来推动创新。与研究机构合作开发生物相似药和新型生物标记可能会进一步推动市场成长。市场仍然充满活力，不断突破，但为了保持竞争力，公司必须应对监管环境并管理成本障碍。透过专注于这些策略，公司可以有效参与新兴趋势、利用新技术并回应全球癌症患者不断变化的需求。

市场动态：揭示快速发展的癌症生物治疗市场的关键市场洞察

供需的动态交互作用正在改变癌症生物治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 由于医疗保健支出增加导致癌症盛行率增加
    • 提高人们对癌症生物治疗益处的认识
    • 政府对癌症治疗的优惠政策
  • 市场限制因素
    • 资本集中处理
  • 市场机会
    • 生物製药的持续技术进步
    • 活性化旨在开发有效癌症生物疗法的研究和开发
  • 市场挑战
    • 抗癌药物治疗的效果

波特五力：驾驭癌症生物治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解癌症生物治疗市场的外部影响

外部宏观环境因素在塑造癌症生物治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解癌症生物治疗市场的竞争格局

对癌症生物治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵癌症生物治疗市场供应商的绩效评估

FPNV定位矩阵是评估癌症生物治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划癌症生物治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对癌症生物治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着医疗费用的增加，癌症发生率也会增加
      • 提高人们对癌症生物治疗益处的认识
      • 政府对癌症治疗的优惠政策
    • 抑制因素
      • 资本集中处理
    • 机会
      • 生物製药的持续技术进步
      • 活性化研发活动以开发有效的生物癌症治疗方法
    • 任务
      • 抗癌药物治疗的预期效果
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癌症生物治疗市场：副产品

  • 癌症生长抑制剂
  • 单株抗体
  • 疫苗

第七章癌症生物治疗市场：依途径途径

  • 肌肉注射
  • 静脉
  • 皮下的

第八章癌症生物治疗市场：依最终用户分类

  • 医院
  • 专业中心

第九章美洲癌症生物治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区癌症生物治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲癌症生物治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie, Inc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Incyte Corp
  • Johnson & Johnson Services, Inc,
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • Sanofi SA
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-B72AD18D0F9C

The Cancer Biological Therapy Market was valued at USD 64.95 billion in 2023, expected to reach USD 72.42 billion in 2024, and is projected to grow at a CAGR of 11.60%, to USD 140.04 billion by 2030.

Cancer biological therapy, often known as immunotherapy, leverages the body's immune system to target and combat cancer cells, encompassing various modalities like monoclonal antibodies, vaccines, and cytokine therapies. As the incidence of cancer continues to rise, there is an increasing necessity for innovative treatments that offer fewer side effects than traditional methods like chemotherapy and radiation. This biologically diverse therapeutic approach has significant applications across numerous cancer types, including melanoma, breast cancer, and leukemia, to name a few. The end-use scope primarily includes hospitals, specialized cancer treatment centers, and research institutes, where tailored biological therapies can be developed based on patient-specific cancer profiles.

KEY MARKET STATISTICS
Base Year [2023] USD 64.95 billion
Estimated Year [2024] USD 72.42 billion
Forecast Year [2030] USD 140.04 billion
CAGR (%) 11.60%

Market growth is largely influenced by technological advancements in biotechnology and a deeper understanding of cancer genomics, alongside an expanding pipeline of biologics and increasing regulatory approvals. The potential opportunities lie in the rising demand for personalized medicine and the rapid development of new therapies addressing previously hard-to-treat cancers. To capitalize on this, companies should invest in R&D for next-generation antibody-drug conjugates and cell-based immunotherapies. However, the market faces challenges such as high treatment costs, complex manufacturing processes, and stringent regulatory requirements that can delay commercialization.

Innovation can be driven by enhancing drug delivery systems to improve efficacy and patient convenience, and exploring the use of artificial intelligence for personalized treatment regimens. Collaborations with research institutions to develop biosimilars and novel biomarkers could further propel market growth. The market remains dynamic, marked by continuous breakthroughs but requires companies to navigate regulatory landscapes adeptly and manage cost barriers to maintain competitiveness. By focusing on these strategies, businesses can effectively engage with emerging trends, leverage new technologies, and address the evolving needs of cancer patients globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biological Therapy Market

The Cancer Biological Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of cancer with increased healthcare expenditure
    • Increasing awareness regarding benefits of cancer biological therapy
    • Favorable government policies for cancer based therapies
  • Market Restraints
    • Capital intensive treatment
  • Market Opportunities
    • Ongoing technological advancements in cancer biologics
    • Rising research and development activities for development of efficient cancer biological therapies
  • Market Challenges
    • Probable effects of anti-cancer drug therapy

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biological Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biological Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biological Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biological Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biological Therapy Market

A detailed market share analysis in the Cancer Biological Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biological Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biological Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biological Therapy Market

A strategic analysis of the Cancer Biological Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biological Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Biogen Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Incyte Corp, Johnson & Johnson Services, Inc,, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., Sanofi SA, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Cancer Biological Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Cancer Growth Blockers, Monoclonal Antibodies, and Vaccines.
  • Based on Route of Administration, market is studied across Intramuscular, Intravenous, and Subcutaneous.
  • Based on End-Users, market is studied across Hospitals and Specialty Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of cancer with increased healthcare expenditure
      • 5.1.1.2. Increasing awareness regarding benefits of cancer biological therapy
      • 5.1.1.3. Favorable government policies for cancer based therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Capital intensive treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing technological advancements in cancer biologics
      • 5.1.3.2. Rising research and development activities for development of efficient cancer biological therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Probable effects of anti-cancer drug therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Biological Therapy Market, by Product

  • 6.1. Introduction
  • 6.2. Cancer Growth Blockers
  • 6.3. Monoclonal Antibodies
  • 6.4. Vaccines

7. Cancer Biological Therapy Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intramuscular
  • 7.3. Intravenous
  • 7.4. Subcutaneous

8. Cancer Biological Therapy Market, by End-Users

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Specialty Centers

9. Americas Cancer Biological Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Biological Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Biological Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc
  • 2. Amgen Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Bausch Health Companies Inc.
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. bluebird bio, Inc.
  • 9. Bristol-Myers Squibb Company
  • 10. Eisai Co., Ltd.
  • 11. Eli Lilly and Company
  • 12. F. Hoffmann-La Roche Ltd
  • 13. Gilead Sciences, Inc.
  • 14. GlaxoSmithKline PLC
  • 15. Hikma Pharmaceuticals PLC
  • 16. Incyte Corp
  • 17. Johnson & Johnson Services, Inc,
  • 18. Merck & Co., Inc.
  • 19. Novartis AG
  • 20. Otsuka Pharmaceutical Co., Ltd
  • 21. Pfizer Inc.
  • 22. Sanofi SA
  • 23. Spectrum Pharmaceuticals, Inc.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. CANCER BIOLOGICAL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER BIOLOGICAL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER BIOLOGICAL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER BIOLOGICAL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER GROWTH BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023